Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

Not defensive Deb, just asking for you to stop repeating verifiably untrue info. I notice you've sidestepped that one again, and still push that the MD is overpaid. Maybe there's a discussion to be had there, but it should be factually based.

I'd have to check your jobkeeper figures, but given when Jobkeeper ended, I assume those staff figures included the expensive rep. staff force needed to support the VMS business. MDC has since divested that side of the business precisely due to those overheads with some significant capex savings, which I would call good management.

Concrete revenue is a different issue and imo depends how you consider Medlab, pot stock or biotech? Biotechs have very high R&D expenses with very long timeframes to obtain regulatory approvals and begin commercialisation. If/when they get there, revenues can be extremely high and happen quickly, but that's the risk/reward on biotechs requiring research and clinical trials for new drugs.

Could you give an example of how you think Medlab should be generating revenues prior to FDA/EMA/TGA approvals and patent grants? And who are they giving investors money away to?